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ABSTRACT
Objectives Glaucoma filtering schemes such as the 
Manchester Glaucoma Enhanced Referral Scheme (GERS) 
aim to reduce the number of false positive cases referred 
to Hospital Eye Services. Such schemes can also have 
wider system benefits, as they may reduce waiting times 
for other patients. However, previous studies of the cost 
consequences and wider system benefits of glaucoma 
filtering schemes are inconclusive. We investigate the cost 
consequences of the Manchester GERS.
Design Observational study.
Methods A cost analysis from the perspective of the 
National Health Service (NHS) was conducted using audit 
data from the Manchester GERS.
Results 2405 patients passed through the Manchester 
GERS from April 2013 to November 2016. 53.3% were 
not referred on to Manchester Royal Eye Hospital (MREH). 
Assuming an average of 2.3 outpatient visits to MREH 
were avoided for each filtered patient, the scheme saved 
the NHS approximately £2.76 per patient passing through 
the scheme.
Conclusion Our results indicate that glaucoma filtering 
schemes have the potential to reduce false positive 
referrals and costs to the NHS.
InTRODuCTIOn
Glaucoma is the world’s leading cause of 
irreversible blindness.1 Up to 20% of new 
referrals to Hospital Eye Services (HES) 
(hospital outpatient eye services) in the UK 
are for suspected glaucoma, with the annual 
cost of monitoring patients with this chronic 
condition estimated to be £22.5 million.2 
The National Health Service (NHS) is under 
tight budgetary restrictions3; it is there-
fore necessary that demand for outpatient 
ophthalmology services is managed effec-
tively and efficiently.
Identifying the appropriate patients for 
outpatient hospital care remains an ongoing 
challenge for all UK glaucoma services. A 
concern for ophthalmology services in the UK 
is that a high proportion of referrals (between 
20% and 65%) have been found to be false 
positives.4–6 Shah and Murdoch7 found both 
the percentage and the number of false posi-
tive referrals for suspected glaucoma had 
increased further since the introduction of 
the first National Institute for Clinical Excel-
lence (NICE)glaucoma guideline in 2009. Not 
only do false positive referrals place unnec-
essary demands on overstretched resources, 
but false positive referrals also incur financial 
costs, both for the NHS and for the patient, as 
well as unnecessary anxiety potentially experi-
enced by referred patients.8
Concern regarding false positive refer-
rals associated with glaucoma diagnosis has 
resulted in the introduction of glaucoma 
referral filtering schemes (including repeat 
measures (see figure 1), enhanced case 
finding, and referral refinement schemes9).9 
An example is the Manchester Glaucoma 
Enhanced Referral Scheme (GERS), which 
was initially introduced in 2000 and updated 
in 2013. In this paper, we examine the cost 
consequences of the Manchester GERS by 
considering the total costs of the scheme.
Glaucoma referral filtering schemes
In the UK, most referrals for suspected glau-
coma are generated through opportunistic 
surveillance during sight tests or private eye 
Key messages
What is already known about this subject?
 ► Glaucoma referral filtering schemes aim to reduce 
false positive referrals to Hospital Eye Services (HES) 
and reduce costs to the National Health Service 
(NHS). However, there is mixed evidence concerning 
the costs of filtering schemes.
What are the new findings?
 ► We use audit data to assess the costs associated 
with the Manchester Glaucoma Enhanced Referral 
Scheme (GERS). The Manchester GERS has not 
been costed since Henson et al.10 We find that the 
scheme is cost saving to the NHS if we assume that 
2.2 outpatient visits to the HES are avoided.
How might these results change the focus of 
research or clinical practice?
 ► The findings in this study highlight the need for 
consistent cost assessments of referral filtering 
schemes. The study finds that referral filtering 
schemes may not always be cost saving to the NHS.
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Figure 1 Manchester GERS pathway. GERS, Glaucoma 
Enhanced Referral Scheme; GP, general practitioner; NHS, 
National Health Service.
examinations by community optometrists. These commu-
nity optometrists will refer patients onto HES if they 
suspect glaucoma. The number of patients being referred 
to HES ophthalmology outpatient departments is rapidly 
increasing due to: an ageing population; advances in 
diagnostic and screening tools; until the updated NICE 
guideline of 2017, changes in national and professional 
guidance regarding glaucoma care.9
Glaucoma referral filtering services allow trained prac-
titioners to repeat, enhance or refine their findings for 
patients who have suspected glaucoma in community 
settings, before onward referral to the HES, therefore 
reducing/avoiding unnecessary referrals. Not only does 
the reduction in false positive referrals relieve excess 
demand on overstretched ophthalmology departments, 
but it also has the potential to reduce waiting times for 
other patients. There are different types of filtering 
services: repeat measures schemes include those where 
measures such as intraocular pressure and/or visual fields 
are repeated prior to referral, enhanced case finding 
schemes sees the optometrist undertake a higher level of 
assessment to offer testing, adding value beyond repeat 
measures and finally, glaucoma referral refinement offers 
a level of testing sufficient for diagnosis of glaucoma.
The Manchester GERS is an example of an enhanced 
case finding scheme with a repeat measures filter also 
feeding into the enhanced case finding pathway. Figure 1 
shows the different aspects of the Manchester GERS. 
In the Manchester GERS patients with suspected glau-
coma are referred to a group of trained and accredited 
community optometrists who have undergone specialist 
training in glaucoma, rather than being referred through 
their general practitioner (GP) onto ophthalmology 
outpatient departments. These community optometrists 
work to an agreed assessment protocol and set of referral 
criteria, and, depending on whether or not the patient 
meets these criteria, either refer the patient directly to the 
HES or discharge them back to the care of to their refer-
ring optometrist or GP (see figure 1). Not only does the 
GERS pathway aim to reduce false positive referrals, but 
it also allows patients with suspected glaucoma to be seen 
by a trained specialist optometrist within 20 working days 
of referral. Furthermore, the additional clinical informa-
tion collected by the accredited community optometrist 
means that triage at the hospital ophthalmology depart-
ment can prioritise patients with higher clinical need.
In 2003 Henson et al10 analysed the Manchester scheme 
(then known as a glaucoma referral refinement scheme) 
and found that 42% of patients passing through the 
scheme were not referred onto the Manchester Royal Eye 
Hospital (MREH). This reduction in false positive refer-
rals meant that the scheme reduced costs to the NHS by 
approximately £17 per patient.
Similar glaucoma referral filtering schemes throughout 
the UK have also been found to reduce false positive 
referrals to HES and to be cost saving to the NHS.11 12 
Devarajan et al11 assessed a variation of the Manchester 
GERS with an additional form of refinement for patients 
not referred 12 months later. Devarajan et al11 found the 
Carmarthenshire Glaucoma Referral Refinement Scheme 
to be cost saving at £117 per patient passing through the 
scheme. Parkins and Edgar12 also analysed two glaucoma 
referral filtering schemes within the Bexley Care Trust; 
a glaucoma repeat measurements scheme and a refine-
ment pathway scheme. The authors found the repeat 
measurement scheme demonstrated a substantial cost 
benefit to the NHS, whereas, the onward referral refine-
ment scheme was found to be cost neutral.
Henson et al10 based their analysis on the assumption 
that false positive referrals attending the HES before the 
introduction of the glaucoma referral filtering scheme 
would have had on average 2.3 clinic visits before being 
discharged. Previous cost consequence studies have 
either used values of 2.3 or 2.1 visits to the HES prior 
to discharge (Devarajan et al,11 Parkins and Edgar12 and 
Ratnarajan et al2). All of these studies found glaucoma 
referral filtering schemes to be cost saving. However, 
these studies assume that false positive patients would 
make more than two visits to an eye hospital prior to 
discharge. This figure comes from an audit of new refer-
rals to the MREH in 1997. Due to advances in technology, 
the introduction of payment by results, and amended 
clinical guidelines, it could be possible that the number 
of follow-up visits prior to discharge may have changed 
from Henson et al’s audit in 1997 (Henson et al10).
In 2016 the Royal College of Ophthalmologists and 
College of Optometrists issued Joint College Guidance 
recommending the implementation of glaucoma referral 
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Figure 2 Number of patients passing through the GERS each month. GERS, Glaucoma Enhanced Referral Scheme.
filtering schemes across the UK, where possible, to 
reduce the false positive referral rate to ophthalmology 
services.13 However, the cost consequences of such glau-
coma referral schemes are unclear and previous studies 
indicate that more than one visit to the HES needs to be 
avoided to make the scheme cost saving.10–12
We aim to calculate the costs savings of the Manchester 
GERS from the perspective of the NHS.
DATA
Cost analysis
The Manchester GERS was revised in 2013. Data were 
collected on patients passing through the scheme from 
April 2013 to November 2016. The main change from 
the earlier Manchester glaucoma referral refinement 
scheme was the inclusion of pachymetry (the measure-
ment of central corneal thickness) and a related revision 
of referral criteria based on age, intraocular pressure 
and central corneal thickness, to better reflect the then 
NICE guideline’s treatment algorithm CG8514 and deal 
with concerns about an increase in false positive referrals 
following the introduction of the guideline.7 All patients 
registered with a GP in Manchester who present at a 
community optometrist or GP with any suspect signs of 
glaucoma were eligible to participate in the scheme.
Waiting times and referrals
We also use data from national Hospital Episodes Statis-
tics to examine the impact of the number of referrals on 
waiting times. Hospital Episode Statistics provide infor-
mation on all outpatient hospital appointments across all 
hospital trusts in England. This data allow us to examine 
whether a reduction in the number of people referred to 
HES reduces waiting times for patients at a national level. 
We focused on first referral appointments to ophthal-
mology departments. Using Hospital Episode Statistics, 
we have information on: waiting times; number of refer-
rals; age of patients; and, identifiers for the hospital Trust 
attended for all ophthalmology outpatient appointments 
between April 2008 and March 2012.
MeTHODS
Cost analysis
We calculated the cost of a first outpatient visit to 
ophthalmology by taking the average of the tariffs from 
the national tariff workbook for years 2013–2017 which 
specifies national prices for specific healthcare services 
paid by the NHS. Patients from the participating prac-
tices attended Manchester University NHS Foundation 
Trust (MFT). Therefore, we applied the Market Forces 
Factor of 1.0568 for MFT. This calculation resulted in a 
cost of £114 for a first attendance and £65 for a follow-up 
appointment. Costs of training optometrists, optom-
etrists’ fees and the cost of equipment were collected 
through an audit of the scheme. Savings were calculated 
by multiplying the cost of an outpatient appointment by 
the number of visits avoided through the Manchester 
GERS.
An internal audit of the Manchester scheme found 
that approximately 8% of patients seen through the 
repeat measurements pathway were referred onto the 
Manchester GERS per year. We calculate the average cost 
per patient passing through the repeat measurement 
scheme per year using internal audit data and include 
this cost in our analysis.
We go onto calculate a threshold value of follow-up 
visits to the MREH that would make the scheme cost 
neutral.
Patient and public involvement
No patients were involved in the development of the 
research question and outcomes measures, nor were 
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Table 1 Costs/savings of the Manchester referral refinement GERS from April 2013 to November 2016 based on 2.3 visits 
before discharge
Savings (£) Costs (£) Notes
Cost of patients 
entering from the 
repeat measurement 
scheme
4938.05 Approximately 8% of patients were referred to GERS per year from the 
repeat measures pathway. The average cost of the repeat measurement 
scheme is £27.82 per patient, calculated by the number of patients who 
were seen for an initial assessment (359*£29) and the number of patients 
who were seen for a second examination (124*£25).* The total cost is 
then divided by the number of patients who were assessed in the repeat 
measures scheme per year (£13 436/483). 71 patients seen by the repeat 
measurements scheme are referred onto GERS creating an annual cost of 
£1975.22 (£27.82*71). As we only have data for one financial year for the 
repeat measurements scheme, we then calculated the total average cost 
across the time scale of the trial (two and a half years)
Training of 
optometrists
2500 The training for the revised Manchester GERS took place in 2013 and 
cost £2500
Fees to optometrists 192 400 £80 per assessment for the 2405 patients seen by accredited community 
optometrists
Equipment costs 48 000   
  MREH non-referred 
cases
254 477   1282 patients not referred, one first visit avoided at £114 and 1.3 
follow-up visits avoided at £65
  Total 254 477 247 838   
Savings 6638.95   
Savings per patient 2.76 £6635.95/2405 patients
*This additional GERS pathway cost is not applied in the current operation of GERS. The repeat measures pathway no longer feeds into 
GERS so this cost does not apply as of 2018.
GERS, Glaucoma Enhanced Referral Scheme; MREH, Manchester Royal Eye Hospital.
they involved in the design of the study. No patients were 
asked to advise on the interpretation of the results.
ReSulTS
Cost analysis
18 community optometric practices across Greater 
Manchester participated in the Manchester GERS and 
2405 patients passed through the scheme between April 
2013 and November 2016. Figure 2 shows the distribu-
tion of cases passing through the scheme. The average 
number of patients per month throughout the scheme 
was 53. The distribution of patients is fairly evenly distrib-
uted across months with a reduction in the number of 
cases in December each year.
Henson et al’s10 method of cost analysis is replicated 
in table 1. In total 2405 patients passed through the 
Manchester GERS from April 2013 to November 2016. Of 
these 2405 patients, 1282 (53.3%) were not referred on to 
the MREH. When following the assumptions of Henson 
et al10 that 2.3 outpatient visits to MREH are avoided, the 
scheme is cost saving to the NHS of £6635, equating to 
approximately £ 2.76 per patient (£6635/2405) passing 
through the scheme.
With advances in technology and additional guidance 
for clinicians it could be possible that only one outpatient 
visit to MREH is avoided through the Manchester GERS. 
Therefore, in table 2 we assume that only one outpa-
tient visit is avoided. With this assumption the GERS is 
no longer cost saving and incurs a cost to the NHS of 
£101 690 which is approximately £42.28 per patient 
within the scheme.
Table 3 shows the threshold value of visits before 
discharge to make the Manchester GERS cost neutral. 
Patients need to have an average of 2.22 visits to MREH 
prior to discharge to make the GERS scheme cost neutral.
DISCuSSIOn
Previous research investigating the cost implications 
of glaucoma referral filtering schemes has found these 
schemes to be cost saving to the NHS. However, the 
previous study by Henson et al10 which analysed data from 
the MFT scheme based the cost analysis on a review of 
new referrals made to MREH in 1997. The discrepancy 
between the cost savings in tables 1 and 2 highlights the 
importance of considering the number of visits made to 
HES prior to discharge for false positive patients.
It is difficult to define a false positive patient. If a 
trained and accredited community optometrist is willing 
to discharge a patient to ongoing community care then 
it seems logical that a clinician at the MREH would 
also discharge that patient to community care after just 
one visit (based on the assumption that visual fields are 
performed at the first visit). However, it might be the 
case that once patients are within HES care clinicians 
may be more open to observing the patient over time 
to check that they are true false positives. Based on the 
costs presented in tables 1 and 2, the HES visits before 
discharge would need to be approximately 2.2 or greater 
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Table 2 Costs/savings of the Manchester GERS from April 2013 to November 2016 based on one visit before discharge
Savings (£) Costs (£) Notes
Cost of patients entering from the repeat 
measurements scheme
4938.05 See table 1
Training of optometrists 2500 The training for the relaunched Manchester 
GERS took place in 2013 and cost £2500
Fees to optometrists 192 400 £80 per assessment 2405 patients seen by 
community optometrists
Equipment cost 48 000   
  MREH non referred cases 146 148 1282 patients not referred, one visit avoided at 
£114 per first visit avoided
  Totals 146 148 247 838   
Savings −101 690   
Savings per patient −42.28 101 690/2405 patients
GERS, Glaucoma Enhanced Referral Scheme; MREH, Manchester Royal Eye Hospital.
Table 3 Threshold value of visits before discharge to make the Manchester GERS cost neutral
Threshold value
Patients not 
referred Costs (£) Notes
101 690 Based on one visit to MREH avoided
65 Cost of follow-up visit
1282 1282 patients not referred to MREH due to GERS scheme
1.22 follow-ups £101 690/ (1282*£65)
2.22 visits in total
GERS, Glaucoma Enhanced Referral Scheme; MREH, Manchester Royal Eye Hospital.
to make the scheme cost saving. Using Health Episodes 
Statistics data on outpatient ophthalmology visits from 
2010 to 2012, we found the average number of visits prior 
to discharge for all ophthalmology outpatient patients to 
be 1.57 across all trusts and 1.49 at MFT. This figure is 
not specific to glaucoma referrals but is lower than the 
threshold value calculated to make the GERS scheme 
cost neutral.
The cost analysis does not take into account potential 
capacity constraints of specialist ophthalmology services. 
If hospitals are unable to expand their specialist eye 
services due to a skill shortage it could be that the optimal 
way to spend NHS resources is to provide a referral 
filtering scheme. The filtering scheme can improve 
referral accuracy and provide a community service that 
could otherwise develop a longer hospital waiting list, 
even if this scheme is not cost saving.
One potential limitation with the Manchester GERS is 
that the patients in the scheme who are the true posi-
tives wait longer to be seen in the HES. If a patient was 
not participating in the scheme, they would be referred 
directly to the HES and seen within their time constraint 
(currently 14 weeks). However, through participating in 
the scheme, patients are instead referred to a trained 
and accredited community optometrist who is required 
to see the patient within 20 working days. The GERS 
optometrist will then refer the patient to MREH if they 
suspect glaucoma. This pathway means that patients who 
need to be seen by the HES could potentially be waiting 
an additional 20 working days prior to referral. We do 
not know how long patients within the scheme actually 
wait to be seen by a trained community optometrist. It is 
unlikely that the increase in capacity for MREH through 
not seeing false positives offsets this additional wait. To 
overcome this shortfall and to ensure that GERS is clini-
cally safe, the true positives identified within the scheme 
are risk profiled with criteria for more urgent assessment 
being in place. Furthermore, a false negative evaluation 
of the Manchester GERS has been conducted.15 The 
authors followed a proportion of patients who were not 
referred to the HES. Of 131 patients not referred to HES 
by the Manchester GERS only one patient in this sample 
was found to be a true false negative (met the GERS 
referral criteria but was not referred).
Long waiting times that might rise from a high number 
of false positive referrals can cause disutility to patients 
due to: their time preference, deterioration of health 
while on the waiting list, and anxiety associated with 
waiting for treatment.16 The importance of reducing 
waiting times for treatment has also been highlighted by 
Propper,16 who used contingent valuation to estimate the 
disutility of time spent on a waiting list, which per week 
is equivalent to £19 in 2013 prices. Nikolova et al17 found 
that waiting time for a treatment can have a significant 
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impact on the health outcome of that treatment. After 
controlling for health, the authors found that a longer 
waiting time has a negative and statistically significant 
impact on the health gain from hip and knee replace-
ment surgery. The monetary value of the loss in the 
health-related quality of life for each additional week of 
waiting was found to be £153 per hip replacement and 
£149 for a knee replacement. The findings of Propper16 
and Nikolova et al17 highlight the intrinsic utility that can 
be attached to waiting time for treatment. Therefore, a 
reduction in waiting times through schemes such as the 
Manchester GERS has the potential to improve health 
outcomes for patients, potentially saving the NHS money 
in the long term.
COnCluSIOn
Glaucoma referral filtering schemes have the potential to 
alleviate the pressure facing the HES and reduce waiting 
times for patients. The Manchester GERS resulted in a 
53% reduction in the number of false positive referrals 
to the MREH between April 2013 and November 2016. 
Reducing false positive referrals has associated benefits 
for both the hospital and the patient. However, intro-
ducing additional services also have a cost. Our study 
shows that the Manchester GERS only results in a cost 
saving if more than the threshold value of 2.22 visits to 
MREH is, on average, avoided through the scheme. This 
finding highlights the need for a clear and consistent 
cost analysis of glaucoma referral filtering schemes. A full 
cost and benefit analysis needs to take these wider system 
consequences into account.
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